Field J K, Neville E M, Stewart M P, Swift A, Liloglou T, Risk J M, Ross H, Gosney J R, Donnelly R J
Molecular Genetics and Oncology Group, University of Liverpool, UK.
Br J Cancer. 1996 Dec;74(12):1968-74. doi: 10.1038/bjc.1996.661.
Allelic imbalance or loss of heterozygosity (LOH) has been widely used to assess genetic instability in tumours, and high LOH on chromosome arms 3p, 9p and 17p has been considered to be a common event in non-small-cell lung cancer (NSCLC). We have investigated allelic imbalance in 45 NSCLCs using 92 microsatellite markers on 38 chromosome arms. LOH of 38% was observed on 3p using nine markers, 58% on 9p using 15 markers and 38% on 17p using five markers. Fractional allele loss (FAL) has been calculated for each tumour (FAL is the number of chromosome arms showing LOH/number of informative chromosome arms) and a median FAL value of 0.09 was obtained in the 45 NSCLCs studied. The LOH data were examined on the basis of FAL scores: low FAL (LFAL) (0.00-0.04), medium FAL (MFAL) (0.05-0.13) and high FAL (HFAL) (0.14-0.45) based symmetrically around the median FAL value of 0.09. Tumours with HFAL values showed a very clear polarisation of the LOH data on chromosome arms 3p, 9p and 17p, such that 80% showed loss on 3p, 80% on 9p and 73% on 17p. These incidences of LOH were significantly higher than would be expected, since overall genetic instability in these HFAL tumours ranged from 14% to 45% LOH. Nine of the 14 patients in the LFAL group were found to have no LOH on 3p, 9p or 17p, but five of these had LOH at other sites: i.e. LOH on 5p, 5q, 8p, 13q, 16q and 19q. These results indicate that LFAL patients form a new subset of NSCLC tumours with distinct molecular-initating events, and may represent a discrete genetic population.
等位基因不平衡或杂合性缺失(LOH)已被广泛用于评估肿瘤中的基因不稳定性,并且3号染色体短臂、9号染色体短臂和17号染色体短臂上的高LOH被认为是非小细胞肺癌(NSCLC)中的常见事件。我们使用位于38条染色体臂上的92个微卫星标记,对45例NSCLC中的等位基因不平衡进行了研究。使用9个标记在3p上观察到38%的LOH,使用15个标记在9p上观察到58%的LOH,使用5个标记在17p上观察到38%的LOH。已为每个肿瘤计算了分数等位基因缺失(FAL)(FAL是显示LOH的染色体臂数/信息性染色体臂数),在所研究的45例NSCLC中获得的FAL中位数为0.09。基于FAL评分检查了LOH数据:低FAL(LFAL)(0.00 - 0.04)、中等FAL(MFAL)(0.05 - 0.13)和高FAL(HFAL)(0.14 - 0.45),它们围绕中位数FAL值0.09对称分布。具有HFAL值的肿瘤在3号染色体短臂、9号染色体短臂和17号染色体短臂上显示出非常明显的LOH数据极化,使得80%在3p上显示缺失,80%在9p上显示缺失,73%在17p上显示缺失。这些LOH发生率显著高于预期,因为这些HFAL肿瘤中的总体基因不稳定性范围为14%至45%的LOH。LFAL组的14例患者中有9例在3p, 9p或17p上未发现LOH,但其中5例在其他位点有LOH,即5p、5q、8p、13q、16q和19q上的LOH。这些结果表明,LFAL患者构成了具有独特分子起始事件的NSCLC肿瘤新亚组,并且可能代表一个离散的基因群体。